These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21980133)

  • 1. Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype.
    Emmons MF; Gebhard AW; Nair RR; Baz R; McLaughlin ML; Cress AE; Hazlehurst LA
    Mol Cancer Ther; 2011 Dec; 10(12):2257-66. PubMed ID: 21980133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
    Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
    Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma.
    Gebhard AW; Jain P; Nair RR; Emmons MF; Argilagos RF; Koomen JM; McLaughlin ML; Hazlehurst LA
    Mol Cancer Ther; 2013 Nov; 12(11):2446-58. PubMed ID: 24048737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.
    Damiano JS; Cress AE; Hazlehurst LA; Shtil AA; Dalton WS
    Blood; 1999 Mar; 93(5):1658-67. PubMed ID: 10029595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulated expression and function of the α4β1 integrin in multiple myeloma cells resistant to bortezomib.
    Sevilla-Movilla S; Arellano-Sánchez N; Martínez-Moreno M; Gajate C; Sánchez-Vencells A; Valcárcel LV; Agirre X; Valeri A; Martínez-López J; Prósper F; Mollinedo F; Teixidó J
    J Pathol; 2020 Sep; 252(1):29-40. PubMed ID: 32501543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion.
    Neri P; Ren L; Azab AK; Brentnall M; Gratton K; Klimowicz AC; Lin C; Duggan P; Tassone P; Mansoor A; Stewart DA; Boise LH; Ghobrial IM; Bahlis NJ
    Blood; 2011 Jun; 117(23):6202-13. PubMed ID: 21474670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Romidepsin overcomes cell adhesion-mediated drug resistance in multiple myeloma cells.
    Sripayap P; Nagai T; Hatano K; Kikuchi J; Furukawa Y; Ozawa K
    Acta Haematol; 2014; 132(1):1-4. PubMed ID: 24356056
    [No Abstract]   [Full Text] [Related]  

  • 8. CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.
    Waldschmidt JM; Simon A; Wider D; Müller SJ; Follo M; Ihorst G; Decker S; Lorenz J; Chatterjee M; Azab AK; Duyster J; Wäsch R; Engelhardt M
    Br J Haematol; 2017 Oct; 179(1):36-49. PubMed ID: 28670693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity.
    Michigami T; Shimizu N; Williams PJ; Niewolna M; Dallas SL; Mundy GR; Yoneda T
    Blood; 2000 Sep; 96(5):1953-60. PubMed ID: 10961900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells.
    Nair RR; Emmons MF; Cress AE; Argilagos RF; Lam K; Kerr WT; Wang HG; Dalton WS; Hazlehurst LA
    Mol Cancer Ther; 2009 Aug; 8(8):2441-51. PubMed ID: 19671765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADP-ribosylation factor 1 (ARF1) takes part in cell proliferation and cell adhesion-mediated drug resistance (CAM-DR).
    Xu X; Wang Q; He Y; Ding L; Zhong F; Ou Y; Shen Y; Liu H; He S
    Ann Hematol; 2017 May; 96(5):847-858. PubMed ID: 28238095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications.
    Bjorklund CC; Baladandayuthapani V; Lin HY; Jones RJ; Kuiatse I; Wang H; Yang J; Shah JJ; Thomas SK; Wang M; Weber DM; Orlowski RZ
    Leukemia; 2014 Feb; 28(2):373-83. PubMed ID: 23760401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A role for activator of G-protein signaling 3 (AGS3) in multiple myeloma.
    Shao S; Huang X; Wang Y; He S; Xu X; Zhu X; Yang X; Ding Z; Yao L; Huang Y; Wang C
    Int J Hematol; 2014 Jan; 99(1):57-68. PubMed ID: 24307516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
    Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
    Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
    Hazlehurst LA; Enkemann SA; Beam CA; Argilagos RF; Painter J; Shain KH; Saporta S; Boulware D; Moscinski L; Alsina M; Dalton WS
    Cancer Res; 2003 Nov; 63(22):7900-6. PubMed ID: 14633719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of VLA-4-dependent myeloma cell adhesion to fibronectin and VCAM-1.
    Sanz-Rodríguez F; Ruiz-Velasco N; Pascual-Salcedo D; Teixidó J
    Br J Haematol; 1999 Dec; 107(4):825-34. PubMed ID: 10606891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib.
    Walsby EJ; Pratt G; Hewamana S; Crooks PA; Burnett AK; Fegan C; Pepper C
    Mol Cancer Ther; 2010 Jun; 9(6):1574-82. PubMed ID: 20515939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elucidating the expression and function of Numbl during cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma (MM).
    Huang Y; Huang X; Cheng C; Xu X; Liu H; Yang X; Yao L; Ding Z; Tang J; He S; Wang Y
    BMC Cancer; 2019 Dec; 19(1):1269. PubMed ID: 31888545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism.
    Kobune M; Chiba H; Kato J; Kato K; Nakamura K; Kawano Y; Takada K; Takimoto R; Takayama T; Hamada H; Niitsu Y
    Mol Cancer Ther; 2007 Jun; 6(6):1774-84. PubMed ID: 17575106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis.
    Mori Y; Shimizu N; Dallas M; Niewolna M; Story B; Williams PJ; Mundy GR; Yoneda T
    Blood; 2004 Oct; 104(7):2149-54. PubMed ID: 15138161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.